Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Academic Article uri icon

Overview

abstract

  • The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.

authors

publication date

  • January 26, 2021

Research

keywords

  • COVID-19 Vaccines
  • Macaca fascicularis
  • Spike Glycoprotein, Coronavirus

Identity

PubMed Central ID

  • PMC7834972

Scopus Document Identifier

  • 85100744149

Digital Object Identifier (DOI)

  • 10.1016/j.cell.2021.01.035

PubMed ID

  • 33577765

Additional Document Info

volume

  • 184

issue

  • 5